Lucid Diagnostics Inc.

NasdaqCM:LUCD Stock Report

Market Cap: US$44.9m

Lucid Diagnostics Past Earnings Performance

Past criteria checks 0/6

Lucid Diagnostics's earnings have been declining at an average annual rate of -48%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 70% per year.

Key information

-48.0%

Earnings growth rate

-29.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate70.0%
Return on equityn/a
Net Margin-2,169.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely

Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely

Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio

Aug 11

We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

Revenue & Expenses Breakdown
Beta

How Lucid Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:LUCD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232-53367
30 Sep 232-57378
30 Jun 231-57399
31 Mar 231-604111
31 Dec 220-564011
30 Sep 221-533712
30 Jun 221-453212
31 Mar 221-372510
31 Dec 211-28189
30 Sep 210-20118
30 Jun 210-1587
31 Mar 210-1046
31 Dec 200-835
30 Sep 200-725
31 Dec 190-413
30 Sep 190-422

Quality Earnings: LUCD is currently unprofitable.

Growing Profit Margin: LUCD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LUCD is unprofitable, and losses have increased over the past 5 years at a rate of 48% per year.

Accelerating Growth: Unable to compare LUCD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LUCD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).


Return on Equity

High ROE: LUCD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.